INVESTORS & MEDIA
Corporate Governance
Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
---|---|---|---|---|---|---|---|
Feb 13, 2012 |
SVP Research and Development S
|
SVP Research and Development S | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 28,869 | $113.35 | 88,745 |
Nov 25, 2019 |
EVP Research and Development
|
EVP Research and Development | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 10,000 | -- | 88,079 |
Apr 04, 2011 |
SVP Res and Dev Sciences
|
SVP Res and Dev Sciences | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 31,837 | $45.53 | 84,465 |
Sep 06, 2011 |
SVP Research and Development S
|
SVP Research and Development S | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 34,399 | $65.76 | 84,110 |
Nov 20, 2012 |
SVP Res and Devel Sciences
|
SVP Res and Devel Sciences | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 16,973 | $167.17 | 83,478 |
Sep 07, 2011 |
SVP Research and Development S
|
SVP Research and Development S | Form 4 | Open market or private sale of non-derivative or derivative security | 1,200 | $67.47 | 82,910 |
Dec 19, 2005 |
SVP, PreclinDevel & Biomol Sci
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 82,818 | -- | 82,818 |
Feb 02, 2024 |
EVP Research and Development
|
EVP Research and Development | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 30,750 | $399.66 | 82,769 |
Feb 14, 2012 |
SVP Research and Development S
|
SVP Research and Development S | Form 4 | Open market or private sale of non-derivative or derivative security | 17,694 | $110.35 | 82,518 |
Feb 14, 2012 |
SVP Research and Development S
|
SVP Research and Development S | Form 4 | Open market or private sale of non-derivative or derivative security | 600 | $111.91 | 81,918 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.